html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

panel gastro-intestinal stroma tumor (KIT, PDGFRA)

This test is available for the following conditions:

Conditions > Oncogenetics > Predictive testing (cancer hotspot panel)

Turnaround time
3 weeks

Method

Targeted analysis of one or more variants

Remarks
Targeted analysis of one or more mutations in KIT (NM_000222.2: codons 412-513, 550-591, 628-713, 799-828) and PDGFRA (NM_006206.4: codons 552-596, 632-667, 814-848).Remark:The above mentioned genes are part of the ‘Radboud Cancer Hotspot panel’. Additional clinically relevant mutations in hotspot regions in AKT1, BRAF, CTNNB1, CXCR4, EGFR, ERBB2, EZH2, GNA11, GNAQ, GNAS, H3F3A, H3F3B, HRAS, IDH1, IDH2, JAK2, KRAS, MPL, MYD88, NRAS, PIK3CA, SF3B1 and instability of the MSI markers BAT25, BAT26, NR21, NR24 and NR27 are also reported.

Performing laboratory: Radboudumc
Authorized material(s): FFPE

PANEL

Complete gene panel analysis

€ 476

Add Remove

Go to main content